Display options
Cite
Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-41doi: 10.3747/co.21.1966.
Boulanger, J., Boursiquot, J. N., Cournoyer, G., Lemieux, J., Masse, M. S., Almanric, K., Guay, M. P. (2014). Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Current oncology (Toronto, Ont.), 21(4), e630-41. https://doi.org/10.3747/co.21.1966
Boulanger, J, et al. "Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations." Current oncology (Toronto, Ont.) vol. 21,4 (2014): e630-41. doi: https://doi.org/10.3747/co.21.1966
Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, Guay MP. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014 Aug;21(4):e630-41. doi: 10.3747/co.21.1966. PMID: 25089112; PMCID: PMC4117628.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2014 Aug;21(4):e630-41. doi: 10.3747/co.21.1966.

Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Current oncology (Toronto, Ont.)

J Boulanger, J N Boursiquot, G Cournoyer, J Lemieux, M S Masse, K Almanric, M P Guay,

Affiliations

  1. Institut national d'excellence en santé et services sociaux ( inesss ), Quebec City, QC.
  2. Centre hospitalier de l'Université Laval ( chu de Québec), Quebec City, QC.
  3. Hôpital régional de Saint-Jérôme ( csss de Saint-Jérôme), Saint-Jérôme, QC.
  4. Hôpital du Saint-Sacrement ( chu de Québec), Quebec City, QC.
  5. Hôpital Notre-Dame ( chum ), Montreal, QC.
  6. Hôpital de la Cité-de-la-Santé ( csss de Laval), Laval, QC.
  7. Jewish General Hospital, Montreal, QC.

PMID: 25089112 PMCID: PMC4117628 DOI: 10.3747/co.21.1966

Abstract

BACKGROUND: Although antineoplastic agents are critical in the treatment of cancer, they can potentially cause hypersensitivity reactions that can have serious consequences. When such a reaction occurs, clinicians can either continue the treatment, at the risk of causing a severe or a potentially fatal anaphylactic reaction, or stop the treatment, although it might be the only one available. The objective of the present work was to evaluate the effectiveness of methods used to prevent and treat hypersensitivity reactions to platinum- or taxane-based chemotherapy and to develop evidence-based recommendations.

METHODS: The scientific literature published to December 2013, inclusive, was reviewed.

RESULTS: Premedication with antihistamines, H2 blockers, and corticosteroids is not effective in preventing hypersensitivity reactions to platinum salts. However, premedication significantly reduces the incidence of hypersensitivity to taxanes. A skin test can generally be performed to screen for patients at risk of developing a severe reaction to platinum salts in the presence of grade 1 or 2 reactions, but skin testing does not appear to be useful for taxanes. A desensitization protocol allows for re-administration of either platinum- or taxane-based chemotherapy to some patients without causing severe hypersensitivity reactions.

CONCLUSIONS: Several strategies such as premedication, skin testing, and desensitization protocols are available to potentially allow for administration of platinum- or taxane-based chemotherapy to patients who have had a hypersensitivity reaction and for whom no other treatment options are available. Considering the available evidence, the Comité de l'évolution des pratiques en oncologie made recommendations for clinical practice in Quebec.

Keywords: Hypersensitivity reactions; chemotherapy; desensitization; management; platinum salts; skin testing; taxanes

References

  1. Med Clin North Am. 2010 Jul;94(4):835-52, xiii - PubMed
  2. Clin Cancer Res. 2002 May;8(5):1038-44 - PubMed
  3. Gynecol Oncol. 2005 Nov;99(2):393-9 - PubMed
  4. Oncologist. 2004;9(5):546-9 - PubMed
  5. J Investig Allergol Clin Immunol. 2010;20(2):170-1 - PubMed
  6. J Clin Oncol. 2000 Jan;18(1):136-47 - PubMed
  7. J Clin Oncol. 1997 Sep;15(9):3149-55 - PubMed
  8. J Clin Oncol. 1986 Aug;4(8):1262-9 - PubMed
  9. J Chemother. 2011 Apr;23(2):59-66 - PubMed
  10. J Hematol Oncol. 2010 Mar 26;3:12 - PubMed
  11. Gynecol Oncol. 1999 Mar;72(3):431-2 - PubMed
  12. Clin Rev Allergy Immunol. 2003 Jun;24(3):253-62 - PubMed
  13. Gynecol Oncol. 2001 Sep;82(3):550-8 - PubMed
  14. J Allergy Clin Immunol. 2007 Mar;119(3):726-30 - PubMed
  15. J Clin Oncol. 1996 Feb;14(2):422-8 - PubMed
  16. J Clin Oncol. 2000 Mar;18(6):1212-9 - PubMed
  17. J Clin Oncol. 1995 Jul;13(7):1609-14 - PubMed
  18. Clin Transl Oncol. 2013 Mar;15(3):219-25 - PubMed
  19. Cancer. 2004 Jan 1;100(1):211-2 - PubMed
  20. J Clin Oncol. 2000 Jan;18(1):102-5 - PubMed
  21. Gynecol Oncol. 2002 Mar;84(3):378-82 - PubMed
  22. Gynecol Oncol. 2003 Jun;89(3):429-33 - PubMed
  23. Expert Opin Drug Saf. 2010 Jan;9(1):39-53 - PubMed
  24. Semin Oncol. 1995 Aug;22(4 Suppl 9):75-7 - PubMed
  25. Gynecol Oncol. 2007 Apr;105(1):81-3 - PubMed
  26. Anticancer Drugs. 2004 Jul;15(6):581-5 - PubMed
  27. Br J Cancer. 2001 Nov 2;85(9):1247-50 - PubMed
  28. Anticancer Drugs. 1996 Aug;7 Suppl 2:25-8 - PubMed
  29. Int J Gynecol Cancer. 2009 Oct;19(7):1281-3 - PubMed
  30. Ann Allergy Asthma Immunol. 2009 Mar;102(3):179-87; quiz 187-9, 222 - PubMed
  31. J Clin Oncol. 2010 Jul 10;28(20):3323-9 - PubMed
  32. Cancer Immunol Immunother. 2012 Sep;61(9):1575-84 - PubMed
  33. Biotechnol Annu Rev. 2007;13:345-57 - PubMed
  34. Drug Saf. 2001;24(10):767-79 - PubMed
  35. J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):42-6 - PubMed
  36. Cancer Chemother Pharmacol. 2005 Jul;56(1):91-6 - PubMed
  37. JOP. 2008 Mar 08;9(2):197-202 - PubMed
  38. J Clin Oncol. 2005 Nov 1;23(31):7794-803 - PubMed
  39. Oncol Nurs Forum. 2005 Sep 01;32(5):1027-35 - PubMed
  40. J Clin Oncol. 2005 Sep 1;23(25):6019-26 - PubMed
  41. Oncologist. 2008 Jun;13(6):725-32 - PubMed
  42. Cancer. 2005 Aug 1;104(3):640-3 - PubMed
  43. Oncology. 2001;61(2):129-33 - PubMed
  44. Allergy. 2002;57 Suppl 72:37-40 - PubMed
  45. J Paediatr Child Health. 2012 Jun;48(6):543-4 - PubMed
  46. Anticancer Drugs. 2010 Mar;21(3):333-8 - PubMed
  47. Inflamm Allergy Drug Targets. 2010 Jul;9(3):206-13 - PubMed
  48. J Allergy Clin Immunol. 2009 Jun;123(6):1262-7.e1 - PubMed
  49. Cochrane Database Syst Rev. 2011 May 11;(5):CD003911 - PubMed
  50. Met Based Drugs. 2010;2010: - PubMed
  51. Gynecol Oncol. 2005 Mar;96(3):824-9 - PubMed
  52. Br J Cancer. 2004 Jan 26;90(2):304-5 - PubMed
  53. Chest. 1992 Oct;102(4 Suppl):305S-311S - PubMed
  54. Gynecol Oncol. 2010 Mar;116(3):323-5 - PubMed
  55. J Clin Oncol. 1994 Jun;12(6):1238-44 - PubMed
  56. Curr Pharm Des. 2008;14(27):2778-91 - PubMed
  57. Gynecol Oncol. 2002 Mar;84(3):420-5 - PubMed
  58. J Oncol Pharm Pract. 2011 Sep;17(3):155-9 - PubMed
  59. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):615-20 - PubMed
  60. Int J Gynecol Cancer. 2009 Oct;19(7):1284-7 - PubMed
  61. J Clin Oncol. 2003 Sep 1;21(17):3194-200 - PubMed
  62. J Clin Oncol. 2003 Dec 15;21(24):4611-4 - PubMed
  63. Semin Oncol. 1992 Oct;19(5):458-77 - PubMed
  64. Int Arch Allergy Immunol. 2011;156(3):320-4 - PubMed
  65. Curr Opin Allergy Clin Immunol. 2006 Dec;6(6):476-81 - PubMed
  66. J Allergy Clin Immunol. 2008 Sep;122(3):574-80 - PubMed
  67. J Allergy Clin Immunol. 1996 Oct;98(4):841-3 - PubMed
  68. J Natl Cancer Inst. 1998 Feb 18;90(4):300-6 - PubMed
  69. J Clin Oncol. 2001 Jun 15;19(12):3126-9 - PubMed
  70. J Clin Oncol. 1990 Jul;8(7):1263-8 - PubMed
  71. Gynecol Oncol. 2010 Mar;116(3):326-31 - PubMed
  72. Oncologist. 2007 May;12(5):601-9 - PubMed
  73. Int J Clin Oncol. 2011 Jun;16(3):244-9 - PubMed
  74. Acta Oncol. 2002;41(5):418-24 - PubMed
  75. Arch Gynecol Obstet. 2005 Mar;271(3):267-9 - PubMed

Publication Types